ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the
safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine and nab
paclitaxel (G-nP) in previously untreated subjects with metastatic pancreatic ductal
adenocarcinoma (PDAC)
Phase:
Phase 1
Details
Lead Sponsor:
ProDa BioTech, LLC
Collaborators:
Georgia State University University of Alabama at Birmingham